203 related articles for article (PubMed ID: 18346405)
1. Cost comparisons of managing complex facial basal cell carcinoma: Canadian study.
Lear W; Mittmann N; Barnes E; Breen D; Murray C
J Cutan Med Surg; 2008; 12(2):82-7. PubMed ID: 18346405
[TBL] [Abstract][Full Text] [Related]
2. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up.
Mosterd K; Krekels GA; Nieman FH; Ostertag JU; Essers BA; Dirksen CD; Steijlen PM; Vermeulen A; Neumann H; Kelleners-Smeets NW
Lancet Oncol; 2008 Dec; 9(12):1149-56. PubMed ID: 19010733
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face.
Essers BA; Dirksen CD; Nieman FH; Smeets NW; Krekels GA; Prins MH; Neumann HA
Arch Dermatol; 2006 Feb; 142(2):187-94. PubMed ID: 16490846
[TBL] [Abstract][Full Text] [Related]
4. [Cost analysis of Mohs micrographic surgery in high-risk facial basal cell carcinoma].
Blázquez-Sánchez N; de Troya-Martín M; Frieyro-Elicegui M; Fúnez-Liébana R; Martín-Márquez L; Rivas-Ruiz F
Actas Dermosifiliogr; 2010 Sep; 101(7):622-8. PubMed ID: 20858388
[TBL] [Abstract][Full Text] [Related]
5. Mohs micrographic surgery for basal cell carcinoma: evaluation of the indication criteria and predictive factors for extensive subclinical spread.
Hoorens I; Batteauw A; Van Maele G; Lapiere K; Boone B; Ongenae K
Br J Dermatol; 2016 Apr; 174(4):847-52. PubMed ID: 26595159
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of Mohs micrographic surgery: review of the literature.
Tierney EP; Hanke CW
J Drugs Dermatol; 2009 Oct; 8(10):914-22. PubMed ID: 19852120
[TBL] [Abstract][Full Text] [Related]
7. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face--results of a retrospective study and review of the literature.
Smeets NW; Kuijpers DI; Nelemans P; Ostertag JU; Verhaegh ME; Krekels GA; Neumann HA
Br J Dermatol; 2004 Jul; 151(1):141-7. PubMed ID: 15270883
[TBL] [Abstract][Full Text] [Related]
8. Recurrence rates of periocular basal cell carcinoma following Mohs micrographic surgery: a retrospective study.
Sin CW; Barua A; Cook A
Int J Dermatol; 2016 Sep; 55(9):1044-7. PubMed ID: 27152747
[TBL] [Abstract][Full Text] [Related]
9. Low recurrence rate of head and neck basal cell carcinoma treated with Mohs micrographic surgery: A retrospective study of 1021 cases.
Kuiper EM; van den Berge BA; Spoo JR; Kuiper J; Terra JB
Clin Otolaryngol; 2018 Oct; 43(5):1321-1327. PubMed ID: 29953746
[TBL] [Abstract][Full Text] [Related]
10. Direct Cost-Analysis of Mohs Micrographic Surgery and Traditional Excision for Basal Cell Carcinoma at Initial Margin Clearance.
Sebaratnam DF; Choy B; Lee M; Paver R; Fernández Peñas P
Dermatol Surg; 2016 May; 42(5):633-8. PubMed ID: 27110895
[TBL] [Abstract][Full Text] [Related]
11. [Complete treatment of basal cell carcinoma; cost effectiveness of Mohs micrographic surgery versus conventional excision].
Muche JM; van Rengen A; Mosterd K
Ned Tijdschr Geneeskd; 2017; 161():D1549. PubMed ID: 29303086
[TBL] [Abstract][Full Text] [Related]
12. Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years.
Leibovitch I; Huilgol SC; Selva D; Richards S; Paver R
J Am Acad Dermatol; 2005 Sep; 53(3):445-51. PubMed ID: 16112351
[TBL] [Abstract][Full Text] [Related]
13. Surgical decision making for basal-cell carcinoma of the face.
Feldman S; Pearce DJ; Williford PM
Lancet Oncol; 2008 Dec; 9(12):1119-20. PubMed ID: 19038758
[No Abstract] [Full Text] [Related]
14. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial.
Smeets NW; Krekels GA; Ostertag JU; Essers BA; Dirksen CD; Nieman FH; Neumann HA
Lancet; 2004 Nov 13-19; 364(9447):1766-72. PubMed ID: 15541449
[TBL] [Abstract][Full Text] [Related]
15. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up.
van Loo E; Mosterd K; Krekels GA; Roozeboom MH; Ostertag JU; Dirksen CD; Steijlen PM; Neumann HA; Nelemans PJ; Kelleners-Smeets NW
Eur J Cancer; 2014 Nov; 50(17):3011-20. PubMed ID: 25262378
[TBL] [Abstract][Full Text] [Related]
16. Appropriate use criteria for basal cell carcinoma Mohs surgery at a single center in the face of high-burden skin cancer: a retrospective cohort study.
Fantini BC; Bueno Filho R; Chahud F; Souza CDS
J Dermatolog Treat; 2019 Feb; 30(1):74-80. PubMed ID: 29727201
[TBL] [Abstract][Full Text] [Related]
17. A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption.
Rogers HW; Coldiron BM
J Am Acad Dermatol; 2009 Jul; 61(1):96-103. PubMed ID: 19539843
[TBL] [Abstract][Full Text] [Related]
18. Retrospective audit of patients referred for further treatment following Mohs surgery for non-melanoma skin cancer.
Wee E; Goh MS; Estall V; Tiong A; Webb A; Mitchell C; Murray W; Tran P; McCormack CJ; Henderson M; Hiscutt EL
Australas J Dermatol; 2018 Nov; 59(4):302-308. PubMed ID: 29349770
[TBL] [Abstract][Full Text] [Related]
19. Adamantinoid basal cell carcinoma: a predictor of more-aggressive clinical behavior.
Berk DR; Ball Arefiev KL; Gladstone HB
Dermatol Surg; 2012 Aug; 38(8):1346-50. PubMed ID: 22551358
[TBL] [Abstract][Full Text] [Related]
20. Willingness to Pay for Surgical Treatments for Basal Cell Carcinoma: A Population-Based Cross-Sectional Study.
Kantor J
Dermatol Surg; 2021 Apr; 47(4):467-472. PubMed ID: 33625136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
